X

COVID-19: Frequently Asked Questions

Below are some of the most frequently asked questions CMA has received during the COVID-19 outbreak. By default, the most recent answers will appear up top. You can also filter the FAQ by category. We will update this resource regularly.

More questions? Email communications@cmadocs.org.


Filter FAQ by Category

 

Has the Federal Anti-Kickback Statute been waived because of the COVID-19 pandemic?

posted on

Yes. On April 3, 2020, the U.S. Department of Health and Human Services (HHS) Office of Inspector General (OIG) issued a policy statement of enforcement discretion regarding applicable sanctions under the Federal Anti-Kickback Statute (42 U.S.C. Section 1320a-7b). The Policy Statement is designed to bring Anti-Kickback Statute enforcement in line with the CMS’ blanket waivers regarding sanctions under Stark Law.

The Policy Statement says OIG will not impose sanctions under the Anti-Kickback Statute with respect to remuneration that is covered by Section II.B(1)-(11) of CMS’s blanket waivers. The Policy Statement is silent on Section II.B(18) of the blanket waiver which suspends the writing and signature requirements for certain Stark law exceptions.

The Policy Statement does not expand the CMS blanket waivers. The OIG expressly points out that the enforcement discretion does not apply to “arrangements… that are not covered by the Blanket Waivers (e.g., direct financial relationships between pharmaceutical or device manufacturers and physicians or between providers where there is no physician involved).”

The Policy Statement only applies to conduct on or after April 3, 2020, while CMS’s blanket waivers are retroactive to March 1, 2020. The Policy Statement remains in effect till the termination of CMS’ blanket waivers.

Additional questions regarding this matter can be directed to OIGComplianceSuggestions@oig.hhs.gov.

Source: OIG Policy Statement

| Categories: Fraud and Abuse | Return

Search the FAQ

FAQ Categories

Subscribe to FAQ

Get notified immediately when we publish a new FAQ.

Name

Disclaimer

Your use of the CMA website, including information provided on the COVID 19 Resource Page, is governed by the Terms of Use and Privacy Policy linked below.  All Content on this website, including COVID 19 related content, is general in nature, is provided for informational purposes only, does not constitute medical, ethical, financial, legal, coding, or other advice, and should not be used as the sole basis for decision-making or as a substitute for obtaining competent consultation and specific advice from a physician, attorney, insurer, or other knowledgeable professional. In all instances, situation-specific circumstances necessitate consideration of factors which cannot be and are not addressed herein and the information provided is not entirely inclusive, exclusive, or exhaustive of all reasonable methods or approaches to addressing the situation described. CMA makes no warranty, express or implied, and assumes no medical, ethical, financial, or legal liability or responsibility for the content, or for any method, process, strategy, or approach described or referenced herein and CMA shall not be held liable for the content or use thereof. Any use or adaptation of this information must include these disclaimers.

Not a CMA member?

Join nearly 50,000 physicians making a direct impact on the practice of medicine and the health of California.